Literature DB >> 32727215

Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications.

Zhengke Wang1, Yu Tina Zhao2, Ting C Zhao3.   

Abstract

Cardiovascular diseases are the leading cause of mortality and morbidity worldwide. Histone deacetylases (HDACs) play an important role in the epigenetic regulation of genetic transcription in response to stress or pathological conditions. HDACs interact with a complex co-regulatory network of transcriptional regulators, deacetylate histones or non-histone proteins, and modulate gene expression in the heart. The selective HDAC inhibitors have been considered to be a critical target for the treatment of cardiac disease, especially for ameliorating cardiac dysfunction. In this review, we discuss our current knowledge of the cellular and molecular basis of HDACs in mediating cardiac development and hypertrophy and related pharmacologic interventions in heart disease.

Entities:  

Keywords:  Histone deacetylase; acetylation; cardiovascular disease; deacetylation; epigenetics; hypertrophy

Mesh:

Substances:

Year:  2020        PMID: 32727215      PMCID: PMC7871120          DOI: 10.1177/1535370220944128

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  162 in total

Review 1.  Roles of cardiac transcription factors in cardiac hypertrophy.

Authors:  Hiroshi Akazawa; Issei Komuro
Journal:  Circ Res       Date:  2003-05-30       Impact factor: 17.367

2.  Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.

Authors:  Seol-Hee Kang; Young Mi Seok; Min-ji Song; Hae-Ahm Lee; Thomas Kurz; InKyeom Kim
Journal:  Mol Pharmacol       Date:  2015-02-09       Impact factor: 4.436

Review 3.  Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.

Authors:  Eva Hornig; Markus V Heppt; Saskia A Graf; Thomas Ruzicka; Carola Berking
Journal:  Exp Dermatol       Date:  2016-11       Impact factor: 3.960

4.  Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation.

Authors:  Ana Planavila; Roser Iglesias; Marta Giralt; Francesc Villarroya
Journal:  Cardiovasc Res       Date:  2010-11-29       Impact factor: 10.787

5.  Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.

Authors:  Douglas D Lemon; Todd R Horn; Maria A Cavasin; Mark Y Jeong; Kurt W Haubold; Carlin S Long; David C Irwin; Sylvia A McCune; Eunhee Chung; Leslie A Leinwand; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2011-04-23       Impact factor: 5.000

6.  Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure.

Authors:  Masaya Tanno; Atsushi Kuno; Toshiyuki Yano; Tetsuji Miura; Shin Hisahara; Satoko Ishikawa; Kazuaki Shimamoto; Yoshiyuki Horio
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

Review 7.  Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.

Authors:  Hae Jin Kee; Hyun Kook
Journal:  J Biomed Biotechnol       Date:  2010-11-29

Review 8.  Histone deacetylase inhibitors: Potential in cancer therapy.

Authors:  P A Marks; W-S Xu
Journal:  J Cell Biochem       Date:  2009-07-01       Impact factor: 4.429

Review 9.  The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy.

Authors:  Shin-ichi Oka; Tetsuro Ago; Takanari Kitazono; Daniela Zablocki; Junichi Sadoshima
Journal:  J Mol Med (Berl)       Date:  2009-05-08       Impact factor: 4.599

10.  Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes.

Authors:  Angela Nebbioso; Fabio Manzo; Marco Miceli; Mariarosaria Conte; Lucrezia Manente; Alfonso Baldi; Antonio De Luca; Dante Rotili; Sergio Valente; Antonello Mai; Alessandro Usiello; Hinrich Gronemeyer; Lucia Altucci
Journal:  EMBO Rep       Date:  2009-06-05       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.